Sanofi

Por favor elegí tu país para conocer sobre los productos disponibles

Mucosolvan® Jarabe Forte

Mucosolvan® Forte es un jarabe específicamente diseñado para tratar la tos con flema. Trabaja específica y efectivamente en calmar rápidamente la tos y la garganta. Mucosolvan® es una marca líder mundial.

Descripción

Mucosolvan® Jarabe Forte

Mucosolvan® tres vías de acción5,6,7
  1. Afloja/disuelve la flema
  2. Activa el mecanismo de auto limpieza del cuerpo
  3. Previene formación de nueva flema

Dosificación

Mucosolvan® FORTE

Adultos y niños mayores de 12 años,
2 veces al día, cada 12 horas

Ingredientes

Ambroxol 30 mg/5 ml
Frasco de vidrio de 120 ml

Prospecto interno

Como los productos y sus regulaciones difieren levemente de un país a otro, por favor consultá el prospecto adjunto

Download

Mucosolvan® Jarabe Forte

"1. Grassi C, Luisetti M, Rose V de, Fietta A, Sacchi F, Genghini M, et alBiomedical and functional changes in bronchoalveolar parameters induced by ambroxol treatment of chronic bronchitis.International Symposium Surfactant System of the Lung, Rome, 1983 March 2-4 In: Cosmi EV, Scarpelli EM, editors. Pulmonary Surfactant System. Amsterdam: Elsevier, 361 - 370 (1983)"
2. Prevention of Chronic Bronchitis Exacerbations with Ambroxol (Mucosolvan Retard) An Open, Long-Term, Multicenter Study in 5,635 Patients' Respiration 1989;55(suppl l):84-96
"3. Schulz M, Haemmerlein A, Hinkel U, Weis G, Gillissen ASafety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study.Int J Clin Pharmacol Ther 44 (9), 409 - 421 (2006)" Claim 12 horas:
4 Tai-jun Hang, Meng Zhang, Min Song, Jian-ping Shen, Yin-di Zhang. Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloryde in human plasma by LC-MS/MS (2007). P07-07778
Claim triple mecanismo de acción:
5 Grassi C, Luisetti M, Rose V de, Fietta A, Sacchi F, Genghini M, et al. Biomedical and functional changes in bronchoalveolar parameters induced by ambroxol treatment of chronic bronchitis.International Symposium Surfactant System of the Lung, Rome, 1983 March 2-4 In: Cosmi EV, Scarpelli EM, editors. Pulmonary Surfactant System. Amsterdam: Elsevier , 361-370 (1983) P83-94424
6 Chianese R, Maiorano V, Bisceglie A, Carnimeo N. Controlled clinical trial of a new preparation for the treatment of hypersecretive bronchial pneumopathies.
Arch Med Interna 35 (2) , 139-154 (1983). P85-1211
7 Bonzi G, Reguzzoni G, Geromino A, Negri L. Clinical evaluation of ambroxol in the treatment of acute and chronic broncopneumopathy.
Minerva Pneumol 23 (1) , 61-65 (1984) P85-1431

Disclaimer

Using this link will let you leave a website of Sanofi or to a different domain under the control of Sanofi. In the event that the linked site is not under the control of Sanofi but under the control of a third party or an affiliate in the Sanofi group of companies, Sanofi shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Sanofi of the site.